Fadrozole (CGS 16949A) is a highly potent and selective nonsteroidal aromatase inhibitor (IC50 of 6.4 nM) with potential antineoplastic activity.

3-CETC (3-Cyano-7-ethoxycoumarin) is a novel and potent fluorescent CYP1A1 &1A2 substrate.

Soticlestat is a novel and potent hydroxylase inhibitor.

Brassinazole is a novel and potent inhibitor of brassinosteroid biosynthesis.

Rhapontigenin is a novel and potent analog of resveratrol with multipul bioactivities such as antifungal, anticancer, antioxidant and antibacterial activities.

Galangin is a novel and potent Ca2+ inhibitor.

Chrysosplenetin is a novel and potent polymethoxylated flavonoid.

Schizandrin A is a novel and potent bioactive compound.

DMU2139 is a potent and specific CYP1B1 inhibitor, with IC50s of 9 nM and 795 nM for CYP1B1 and CYP1A1, respectively.

Gentiopicrin is a novel and potent bioactive compound and is naturally occurring iridoid glycoside.